Blog
RSS FeedPosted by Michael Wonder on 23 Apr 2022
Recommendations made by the PBAC - March 2022
22 April 2022 - The recommendations from the March 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 20 Apr 2022
Making #MedicinesMatter for all Australians
21 April 2022 - Medicines Australia has launched a social media campaign to highlight key policy issues for the election ...
Posted by Michael Wonder on 18 Apr 2022
Securing the future of Australia’s world class healthcare system
17 April 2022 - Under the changes announced today, an additional 71,000 Australians will have access to continuous glucose monitoring and ...
Posted by Michael Wonder on 14 Apr 2022
Public summary documents – December 2021 PBAC meeting (first time decisions not to recommend, deferrals and other matters)
14 April 2022 - The Public Summary Documents (first time decisions not to recommend, deferrals and other matters) from the December ...
Posted by Michael Wonder on 11 Apr 2022
New COVID-19 oral treatment on PBS
11 April 2022 - Greg Hunt's swan song press release. ...
Posted by Michael Wonder on 10 Apr 2022
Faster patient access to new medicines must be a priority for next Government
10 April 2022 - With the Federal Election campaign now formally underway, Medicines Australia is reminding the major parties of ...
Posted by Michael Wonder on 10 Apr 2022
Health Technology Assessment Review Reference Committee will drive reform to support Australian patients
10 April 2022 - The Health Technology Assessment Review Reference Committee announced (via the Department of Health website) is tasked ...
Posted by Michael Wonder on 09 Apr 2022
PBS listing of Paxlovid (nirmatrelvir and ritonavir)
9 April 2022 - Commencing 1 May 2022, Paxlovid (nirmatrelvir and ritonavir) will be listed on the PBS as a General ...
Posted by Michael Wonder on 09 Apr 2022
Life Saving Drugs Program – medicines reviews recommendations
7 April 2022 - This document outlines 51 recommendations from the Life Saving Drugs Expert Panel review. ...
Posted by Michael Wonder on 09 Apr 2022
PBAC recommendation for nirmatrelvir and ritonavir (Paxlovid) - March 2022
9 April 2022 - The PBAC undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 05 Apr 2022
Consultation now open - review of base case discount rate at 3A.1 of the PBAC Guidelines
5 April 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment ...
Posted by Michael Wonder on 04 Apr 2022
Mystery solved over Hansard change to hide budget’s missing $10 drug price cut
4 April 2022 - Financial Services Minister Jane Hume’s office asked Hansard staff to delete references to a planned $10 ...
Posted by Michael Wonder on 01 Apr 2022
Price slashed for revolutionary $78,000 a year prostate cancer treatment Lynparza
1 April 2022 - A new subsidy for a revolutionary drug is set to benefit thousands of Aussie men with aggressive ...
Posted by Michael Wonder on 01 Apr 2022
Making medicines more affordable for more Australians
1 April 2022 - Australians will have cheaper access to treatments for high cholesterol, heart failure and high blood pressure from ...
Posted by Michael Wonder on 01 Apr 2022
Public Summary Documents – December 2021 PBAC meeting
1 April 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the December 2021 PBAC ...